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For several reasons, the value of placebo-controlled trials has
often been disputed (not only) in complementary/alternative
medicine (CAM) (1). Many clinicians feel that giving pla-
cebos to suffering patients is unethical. In fact, the Declara-
tion of Helsinki advocates placebo-controlled trials only for
conditions for which no therapy of proven efficacy exists (2).
Other frequently cited reasons against the use of placebos in
controlled clinical trials include the notions that patients find
them hard to accept, that the placebo effect is an important
contributor to the overall therapeutic effect, which should be
cultivated rather than eliminated, and that placebo effects
interact in a complex way with specific therapeutic effects,
which renders the entire concept of the placebo-controlled
trial an unscientific over-simplification (1). At the very mini-
mum, placebo-controlled studies can be difficult to conduct,
and it is therefore obvious that researchers should look for
other types of methodology.
Two such options that potentially still retain major design
features (namely blinding and randomization to a compara-
tor treatment) of rigorous clinical trials are the non-inferior-
ity trial (NIT) and the equivalence trial (ET). NITs test the
hypothesis that one therapy is not worse than another, while
ETs are aimed at finding out whether one treatment is neither
better nor worse than another. In CAM, as in many other
areas of medicine, it is often relevant to ask, is therapy X as
good (i.e. efficacious) as therapy Y (i.e. another treatment
used for the same condition)? For instance, in palliative
cancer care it may be much more relevant to know whether
massage therapy yields the same benefit in terms of quality
of life as does aromatherapy, compared to determining
whether massage is different from a placebo intervention.
NITs and ETs are designed to answer such questions and are
therefore potentially useful—in CAM and other areas of
medical research.
At first glance, NITs and ETs look very much like conven-
tional studies. They have a comparison group, can be ran-
domized and even double-blind. Yet there is one crucial
difference: while conventional studies aim to test whether
there is a difference between the experimental and the
control treatment, NITs and ETs aim to test whether both
interventions yield the same (equivalent) result (3).
Despite the fact that such studies seem ideally suited to
answer many research questions in CAM, they are associated
with several major drawbacks. First, the sample size of a
typical NIT or ET has to be substantially larger than that of
a typical conventional trial. For a conventional superiority
trial, one needs to define what is clinically different (e.g. a dif-
ference of 5 points on a scale to arrive at an estimated sample
size). For a NIT or an ET, one has to define what is clinically
non-superior or equivalent. Common sense says that this
must be less (e.g. plus or minus 2 points on the scale), thus
the sample size of a typical NIT/ET needs to be larger.
Analysis is different too: NITs and ETs require confidence
intervals. One also needs to be quite clear whether one is
doing a strict ET, i.e. no better and no worse, or a NIT, i.e.
no worse. The implications can be considerable, particularly
in CAM where research funding is usually at a premium (4).
For example, while a conventional (placebo-controlled) study
with, say, 200 patients is (at least sometimes) fundable, one
with 400 patients very rarely is!
Second, equivalence or non-superiority only makes sense if
the compactor treatment is of proven efficacy. Worse, one
must make sure that, in the trial, one gives the comparator
treatment its best chance of success. This usually means using
it under the same conditions as those in which it was origi-
nally shown to be effective, and on a similar population. In
other words, doses, inclusion and exclusion criteria etc must
be the same as in the original trials. This can be a problem
for CAM where one often wants to treat mild to moderate
symptoms, whereas in a typical superiority trial one might
opt to exclude mild to moderate symptoms.
If the comparator treatment is not of proven efficacy,
establishing equivalence or non-inferiority between the
experimental and the two treatments can be interpreted in at
least two (dramatically different) ways: treatment A is equally
effective as B, or it is equally ineffective as B. In the latter
case, the result would obviously be less than informative (5).
Important implications arise here for CAM: situations where
a therapeutic option of proven efficacy exists are few and far
between. The usual CAM scenario is a setting where several
CAM therapies are used but none are of proven efficacy.
Some would even insist that lack of proof of efficacy is a hall-
mark of CAM (6), in which case NITs or ETs of one form of
CAM versus another hardly seem to be a good idea. NITs
and ETs of one form of CAM versus an orthodox therapy,
on the other hand, may encounter some of the above-listed10 Editorial
problems typical of placebo-controlled studies, e.g. reserva-
tions of participating patients.
And what about trials in which one active treatment A is
tested against another active therapy B but which are not
designed as NITs or ETs? In recent years such trials have
become more and more frequent in CAM, but what do they
show? If A turns out to be superior to B, then this is precisely
what they show. However, more often than not, A is not
significantly different from B and the authors use language
suggesting that this means they are ‘similar’ or ‘equal’ or
‘equipotent’. This terminology is seriously misleading. All
that such a trial shows is that the result was inconclusive and
thus there was no difference: in common English the differ-
ence seems minute; in terms of statistics it is, however,
considerable.
In conclusion, NITs and ETs seem to be an attractive alter-
native to conventional, placebo-controlled, superiority trials
of CAM. We are therefore likely to see more and more of
such investigations. However, it is crucial to ensure that they
are properly designed and that their conclusions are correct.
Studies incorrectly posing as NITs or ETs can be seriously
misleading.
Acknowledgment
I am grateful to Anna Hart for her comments on this manu-
script.
References
1. Heusser P. Probleme von Studiendesigns mit Randomisation, Verblind-
ung und Placebogabe. Forsch Komplementarmed 1999;6:89–102.
2. World Medical Association. The Declaration of Helsinki (Doc 17.c).
2002.
3. Jadad AR. Randomised controlled trials. A user’s guide. London, UK:
BMJ Books 1998.
4. Ernst E. Funding research into complementary medicine: the situation
in Britain. Complement Ther Med 1999;7:250–3.
5. Yueh B. On equivalence trials and alternative medicine. Arch Otolaryn-
gol Head Neck Surg 2003;129:403–4.
6. Eisenberg DM, et al. Unconventional medicine in the United States.
N Engl J Med 1993;328:246–52.